A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis.

Jenni, D; Karpova, M B; Mühleisen, B; Mangana, J; Dreier, J; Hafner, J; Dummer, R

Jenni, D; Karpova, M B; Mühleisen, B; Mangana, J; Dreier, J; Hafner, J; Dummer, R.

Afiliação

Jenni D; Department of Dermatology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Karpova MB; Department of Dermatology, University Hospital Zürich, University of Zürich, Zürich, Switzerland; Department of Roche Pharmaceutical Research & Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.
Mühleisen B; Department of Dermatology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Mangana J; Department of Dermatology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Dreier J; Department of Dermatology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Hafner J; Department of Dermatology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Dummer R; Department of Dermatology, University Hospital Zürich, University of Zürich, Zürich, Switzerland. Electronic address: reinhard.dummer@usz.ch.

ESMO Open ; 1(1): e000003, 2016.

Article em En | MEDLINE | ID: mdl-27843579

Palavras-chave

Advanced cutaneous squamous cell carcinoma; EGFR-inhibitors; lapatinib; options beyond chemotherapy; primary and secondary preve

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 3_ND Problema de saúde: 3_diarrhea Tipo de estudo: Clinical_trials / Guideline / Risk_factors_studies Idioma: En Revista: ESMO Open Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google